Key Findings
The MC-GelMA hydrogel system demonstrated the ability to maintain lung cancer organoids (LCOs) with in vivo-like morphology, enhanced viability, and metabolic activity compared to Matrigel. The platform supported stable long-term culture through passage 9 while preserving drug sensitivity and key genomic and histological features. In co-culture experiments with PBMCs, the system successfully recapitulated anti-PD-L1 responses, where PD-L1-positive organoids showed increased LDH release, while PD-L1-negative organoids remained unresponsive.
Technical Details
The biomimetic hydrogel was constructed by integrating two patient-derived autologous components into a porous gelatin methacryloyl (GelMA) network:
- Decellularized lung fiber fragments: These fibers, measuring 1.25 μm in diameter and 52.5 μm in length, provided essential structural and mechanical cues.
- Optimized autologous plasma: Processed at 56 °C for 30 min and centrifuged at 8,000×g for 5 min (5% v/v), the plasma supplied necessary biochemical signals.
The resulting MC-GelMA exhibited a Young’s modulus of 15.67 ± 0.86 kPa, closely matching the mechanical properties of native lung tumor tissue. The study compared five formulations—GelMA, GelMA+ fiber, GelMA + plasma, MC-GelMA, and Matrigel—to determine that the combination of fibers and plasma synergistically enhanced organoid growth and immune cell infiltration.
Background & Context
Traditional LCO culture relies heavily on Matrigel, which is limited by undefined composition, immunogenicity, and batch-to-batch variability. These factors often compromise experimental reproducibility and the accuracy of drug response readouts. To address this, the researchers developed a more reproducible biofabrication platform using patient-derived materials.
Significance & Outlook
This autologous component-integrated system provides a highly reproducible platform for stable LCO culture and the reliable recapitulation of patient-specific immunotherapy response patterns. The researchers note that further validation in larger cohorts is required to establish the platform’s predictive potential for clinical immunotherapy outcomes.
Source: https://doi.org/10.1088/1758-5090/aec19a
Get our weekly technology intelligence — free
Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.
Subscribe Free — Weekly Tech Intelligence
By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.
- Your email and selected fields are used only to deliver the newsletter.
- We never share your information with third parties.
- You can unsubscribe anytime via the link in each email.
See our Privacy Policy for details.
Takes about a minute · Unsubscribe anytime



